ESR1 and breast carcinoma: ARV-825 was effective when combined with tamoxifen in both p53 wild type and p53 null ER+ breast cancer cell lines while ABBV-744 showed effectiveness only in combination with fulvestrant plus palbociclib in p53 wild-type cells.